Amylin Pharmaceuticals Inc - Current report filing (8-K)
March 13 2008 - 4:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
March 12, 2008
Amylin Pharmaceuticals, Inc.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
0-19700
|
|
33-0266089
|
(State or other
jurisdiction of incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
9360
Towne Centre Drive
San
Diego, California
|
|
92121
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
(858) 552-2200
Not Applicable.
(Former name or
former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
1.01 Entry into a Material
Definitive Agreement.
On March 12, 2008, we
entered into a second amendment to our Rights Agreement, dated as of June 17,
2002 and as amended on December 13, 2002, with American Stock Transfer &
Trust Company (the Rights Agreement). The second amendment to the Rights
Agreement allows Eastbourne Capital
Management, LLC and affiliates thereof (Eastbourne)
to acquire up to 19.99% of our outstanding common stock under certain
circumstances without becoming an Acquiring Person under the Rights
Agreement, which would result in certain adverse consequences to Eastbourne.
The amendment will lapse by its terms upon
the termination of a separate agreement between us and Eastbourne, as described
below. A copy of the second amendment to
the Rights Agreement is attached hereto as Exhibit 4.1.
Also on March 12, 2008, we
entered into an agreement with Eastbourne concerning Eastbournes ownership of
our common stock (the Ownership Agreement).
Pursuant to the Ownership Agreement, Eastbourne is obligated to vote any
shares of our common stock it owns in excess of 15% of the total outstanding
shares in accordance with the recommendation to the stockholders generally made
by our board of directors in any proxy solicitation and grants us an
irrevocable proxy to vote those shares in accordance with the Ownership
Agreement. In addition, Eastbourne
agreed (a) not to dispose of any shares of our common stock except in open
market transactions, (b) not to short our common stock and (c) to use
reasonable efforts to prevent its shares of our common stock from being
margined, loaned or otherwise made available for short sales except to the
extent required under Eastbournes existing agreements with third parties. The Ownership Agreement also includes a
standstill during the term of the agreement that prohibits Eastbourne from
initiating or participating in other activities or transactions with respect to
us, including (i)
an
acquisition of 20% or more of our outstanding common stock, (ii) enumerated
change of control transactions, including tender or exchange offers, (iii) solicitation
of proxies from our stockholders and (v) making stockholder proposals or
recommendations for election of directors except that Eastbournes standstill
does not apply to transactions supported by a majority of our board of
directors or to Eastbourne passively tendering shares in a third party tender
offer so long as Eastbourne did not violate the other standstill
provisions. The Ownership Agreement will
terminate automatically if Eastbourne fails to become a beneficial owner of
more than 15% of our common stock within 90 days of the agreement or
Eastbourne, after acquiring beneficial ownership of 15% or more of our common
stock, subsequently reduces its beneficial ownership below 15% or no longer
qualifies to file a Schedule 13G.
A copy of the Ownership
Agreement is attached hereto as Exhibit 99.1.
The foregoing description of the
second amendment to the Rights Plan and the Ownership Agreement does not
purport to be complete and is qualified in its entirety by reference to
Exhibits 4.1 and 99.1 hereto.
Item 3.03 Material
Modification to Rights of Security Holders.
The information
set forth under Item 1.01 of this Current Report on Form 8-K is
incorporated herein by reference.
2
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
|
|
Exhibit Description
|
4.1
|
|
Second Amendment to Rights Agreement, dated March 12, 2008,
between Amylin Pharmaceuticals, Inc. and American Stock
Transfer & Trust Company.
|
|
|
|
99.1
|
|
Agreement, dated March 12, 2008, between Amylin
Pharmaceuticals, Inc.,
Eastbourne Capital Management, LLC, Black Bear Offshore
Master Fund, L.P., and Richard J. Barry
|
3
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Lloyd A.
Rowland
|
|
|
Lloyd A. Rowland
|
|
|
Vice
President, Governance and
Compliance and Secretary
|
|
|
|
Date:
March 13, 2008
|
|
|
4
EXHIBIT INDEX
Exhibit
Number
|
|
Exhibit Description
|
4.1
|
|
Second Amendment to Rights Agreement, dated March 12, 2008,
between Amylin Pharmaceuticals, Inc. and American Stock
Transfer & Trust Company.
|
|
|
|
99.1
|
|
Agreement, dated March 12, 2008, between Amylin
Pharmaceuticals, Inc.,
Eastbourne Capital Management, LLC, Black Bear
Offshore Master Fund, L.P., and Richard J. Barry
|
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024